BRPI0715331B8 - polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo - Google Patents
polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmoInfo
- Publication number
- BRPI0715331B8 BRPI0715331B8 BRPI0715331A BRPI0715331A BRPI0715331B8 BR PI0715331 B8 BRPI0715331 B8 BR PI0715331B8 BR PI0715331 A BRPI0715331 A BR PI0715331A BR PI0715331 A BRPI0715331 A BR PI0715331A BR PI0715331 B8 BRPI0715331 B8 BR PI0715331B8
- Authority
- BR
- Brazil
- Prior art keywords
- terminal portion
- polypeptide
- polypeptides
- seq
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
derivados de citoquina. a presente invenção refere-se a polipeptídeos que compreendem uma parcela n-terminal e uma parcela c-termina, sendo que cada parcela n-terminal compreende a sequência de assinatura qgp[p ou l] e a seuquência de aminoácido da referida parcela c- terminal é pelo menos 70% idêntica à seq in no: 1, seus empregos.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0614755.7 | 2006-07-25 | ||
| GB06147557 | 2006-07-25 | ||
| GBGB0614755.7A GB0614755D0 (en) | 2006-07-25 | 2006-07-25 | Cytokine derivatives |
| PCT/IB2007/003026 WO2008012689A2 (en) | 2006-07-25 | 2007-07-25 | Cytokine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0715331A2 BRPI0715331A2 (pt) | 2013-07-16 |
| BRPI0715331B1 BRPI0715331B1 (pt) | 2021-04-13 |
| BRPI0715331B8 true BRPI0715331B8 (pt) | 2021-05-25 |
Family
ID=37006114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0715331A BRPI0715331B8 (pt) | 2006-07-25 | 2007-07-25 | polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8686111B2 (pt) |
| EP (1) | EP2076532B1 (pt) |
| JP (1) | JP5224603B2 (pt) |
| KR (1) | KR101530353B1 (pt) |
| CN (1) | CN101511867B (pt) |
| AT (1) | ATE490270T1 (pt) |
| AU (1) | AU2007278894B2 (pt) |
| BR (1) | BRPI0715331B8 (pt) |
| CA (1) | CA2658806C (pt) |
| CY (1) | CY1111630T1 (pt) |
| DE (1) | DE602007010969D1 (pt) |
| DK (1) | DK2076532T3 (pt) |
| ES (1) | ES2361455T3 (pt) |
| GB (1) | GB0614755D0 (pt) |
| HR (1) | HRP20110146T1 (pt) |
| ME (1) | ME01320B (pt) |
| MX (1) | MX2009000918A (pt) |
| NZ (1) | NZ575092A (pt) |
| PL (1) | PL2076532T3 (pt) |
| PT (1) | PT2076532E (pt) |
| RS (1) | RS51854B (pt) |
| RU (1) | RU2461567C2 (pt) |
| SI (1) | SI2076532T1 (pt) |
| WO (1) | WO2008012689A2 (pt) |
| ZA (1) | ZA200901342B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201600091033A1 (it) * | 2016-09-08 | 2018-03-08 | Bioimmunizer Sagl | Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti. |
| WO2019229616A1 (en) | 2018-05-28 | 2019-12-05 | Orion Biotechnology Switzerland Sàrl | Ccr5 inhibitor for use in treating cancer |
| CN112469430B (zh) * | 2018-05-28 | 2024-12-24 | 日内瓦大学 | 抑制大脑炎症的方法 |
| EP4646232A1 (en) | 2023-01-06 | 2025-11-12 | Université de Genève | Variant ligand conjugates for payload delivery |
| WO2025172252A1 (en) | 2024-02-15 | 2025-08-21 | Novo Nordisk A/S | Protracted ccr5 antagonists and uses thereof |
| WO2025176787A1 (en) | 2024-02-22 | 2025-08-28 | Orion Biotechnology Holding Sa | Ccl5 variants for modulating gpr75 |
| WO2025186255A1 (en) | 2024-03-06 | 2025-09-12 | Orion Biotechnology Holding Sa | Gipr inhibitors and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2201421C2 (ru) * | 1993-06-09 | 2003-03-27 | Коннот Лабораториз Лимитед | Синтетический пептид hiv (варианты), иммуногенная композиция для индукции иммунного ответа против пептидов hiv, диагностический набор для определения hiv-специфичных антител |
| FR2748938B1 (fr) * | 1996-05-22 | 1998-07-31 | Pasteur Institut | Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih |
| UA77950C2 (en) | 2000-10-04 | 2007-02-15 | Applied Research Systems | Use of mutants of cc chemokines for treatment of multiple sclerosis |
| US20030049603A1 (en) * | 2001-09-05 | 2003-03-13 | Guy Gorochov | Methods for construction and screening of libraries of chemokine variants |
| US7442512B2 (en) * | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| WO2005112567A2 (en) | 2004-05-03 | 2005-12-01 | University Of Maryland Biotechnology Institute | Vaginal microbicide |
-
2006
- 2006-07-25 GB GBGB0614755.7A patent/GB0614755D0/en not_active Ceased
-
2007
- 2007-07-25 DK DK07825334.1T patent/DK2076532T3/da active
- 2007-07-25 SI SI200730500T patent/SI2076532T1/sl unknown
- 2007-07-25 CN CN200780032719.1A patent/CN101511867B/zh active Active
- 2007-07-25 WO PCT/IB2007/003026 patent/WO2008012689A2/en not_active Ceased
- 2007-07-25 PL PL07825334T patent/PL2076532T3/pl unknown
- 2007-07-25 PT PT07825334T patent/PT2076532E/pt unknown
- 2007-07-25 AT AT07825334T patent/ATE490270T1/de active
- 2007-07-25 CA CA2658806A patent/CA2658806C/en active Active
- 2007-07-25 MX MX2009000918A patent/MX2009000918A/es active IP Right Grant
- 2007-07-25 AU AU2007278894A patent/AU2007278894B2/en active Active
- 2007-07-25 BR BRPI0715331A patent/BRPI0715331B8/pt active IP Right Grant
- 2007-07-25 JP JP2009521377A patent/JP5224603B2/ja active Active
- 2007-07-25 ES ES07825334T patent/ES2361455T3/es active Active
- 2007-07-25 NZ NZ575092A patent/NZ575092A/en not_active IP Right Cessation
- 2007-07-25 US US12/309,569 patent/US8686111B2/en active Active
- 2007-07-25 ME MEP-2011-47A patent/ME01320B/me unknown
- 2007-07-25 RS RS20110103A patent/RS51854B/sr unknown
- 2007-07-25 KR KR1020097003947A patent/KR101530353B1/ko active Active
- 2007-07-25 EP EP07825334A patent/EP2076532B1/en active Active
- 2007-07-25 DE DE602007010969T patent/DE602007010969D1/de active Active
- 2007-07-25 RU RU2009106436/10A patent/RU2461567C2/ru active
- 2007-07-25 HR HR20110146T patent/HRP20110146T1/hr unknown
-
2009
- 2009-02-24 ZA ZA2009/01342A patent/ZA200901342B/en unknown
-
2011
- 2011-02-23 CY CY20111100216T patent/CY1111630T1/el unknown
-
2013
- 2013-06-04 US US13/909,845 patent/US9328153B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ600731A (en) | Oxyntomodulin peptide analogue | |
| ES2534744T3 (es) | Plasmina modificada de forma recombinante | |
| NZ627111A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| NO20063026L (no) | Antistoffer | |
| NZ600732A (en) | Oxyntomodulin peptide analogue | |
| BRPI0715331B8 (pt) | polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo | |
| IN2014CN02050A (pt) | ||
| PE20120358A1 (es) | Mutantes fgf21 y usos de los mismos | |
| DE502005006284D1 (de) | Keratin-bindende polypeptide | |
| UA103215C2 (uk) | Поліпептид з ксиланазною активністю | |
| NZ609216A (en) | Anticancer fusion protein | |
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| MY148447A (en) | Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases | |
| WO2010007144A3 (en) | Mutated netrin-4 proteins, fragments thereof and their uses as drugs | |
| DK1587830T3 (da) | Peptidinhibitorer af toksiner stammende fra LL-37 | |
| NZ601647A (en) | Variant hhip1 protein and methods and uses thereof | |
| MX2010010213A (es) | Peptido parcial de lacritina. | |
| GEP20115196B (en) | Neublastin variants | |
| ES2557938T3 (es) | Antagonistas de resistina y su uso | |
| EA201590431A1 (ru) | Пшеница с новыми аллелями rht-b1 | |
| NZ591133A (en) | Novel melanoma antigen peptide and uses thereof | |
| WO2006097432A3 (de) | Keratin-biktdende desmoplakinpolypeptidsequenzen | |
| BRPI0508916A (pt) | polipeptìdeos hìbridos imunogênicos antiobesidade e composição de vacina antiobesidade compreendendo-os | |
| ES2421885T3 (es) | Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia | |
| ATE466876T1 (de) | Immunogene konstrukte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: MINTAKA FOUNDATION FOR MEDICAL RESEARCH (CH) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: ORION BIOTECHNOLOGY SWITZERLAND SARL (CH) |
|
| B25G | Requested change of headquarter approved |
Owner name: ORION BIOTECHNOLOGY SWITZERLAND SARL (CH) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/07/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/07/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |